Australian Streptokinase Trial "ASK"

Completed

Phase 3 Results

Summary of Purpose

To determine whether the administration of 1.5 million units of streptokinase intravenously within 4 hours of the onset of acute ischemic stroke would reduce morbidity and mortality at 3 months and whether outcomes may be better for those receiving therapy within 3 hours of stroke onset compared with those receiving it after 3 hours.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 5 October 2000.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Trial Design

Randomized, double-blind, placebo-controlled trial involving 340 patients at 40 centers throughout Australia.

Contacts

Not available